OXFORD Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>OB</div>
OXBDF -- USA Stock  

USD 10.57  0.19  1.83%

OXFORD BIOMEDICA is currently producing 0.1829% returns and takes up 3.1221% volatility of returns over 60 trading days. While many risk-averse shareholders are getting carried away by overanalyzing healthcare space, it is reasonable to digest OXFORD BIOMEDICA. What exactly are OXFORD BIOMEDICA shareholders getting in October? OXFORD BIOMEDICA's seemingly stabilizing volatility may still impact the value of the otc stock as we estimate OXFORD BIOMEDICA as currently overvalued. The real value, based on our calculations, is getting close to 9.02 per share.
Published over a month ago
View all stories for OXFORD BIOMEDICA | View All Stories
Will shareholders trade more of OXFORD BIOMEDICA in October?
The company classifies itself under Healthcare sector and is part of Biotechnology industry.
Volatility is a rate at which the price of OXFORD BIOMEDICA or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of OXFORD BIOMEDICA may increase or decrease. In other words, similar to OXFORD's beta indicator, it measures the risk of OXFORD BIOMEDICA and helps estimate the fluctuations that may happen in a short period of time. So if prices of OXFORD BIOMEDICA fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our technical analysis page.

How important is OXFORD BIOMEDICA's Liquidity

OXFORD BIOMEDICA financial leverage refers to using borrowed capital as a funding source to finance OXFORD BIOMEDICA ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. OXFORD BIOMEDICA financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between OXFORD BIOMEDICA's total debt and its cash.

How OXFORD utilizes its cash?

To perform a cash flow analysis of OXFORD BIOMEDICA, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash OXFORD BIOMEDICA is receiving and how much cash it distributes out in a given period. The OXFORD BIOMEDICA cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

A Deeper Perspective

The modest gains experienced by current holders of OXFORD BIOMEDICA may encourage shareholders to take a closer look at the company as it is trading at a share price of 11.00 on slow start in trading volume. The company directors and management have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in August. The stock standard deviation of daily returns for 30 days investing horizon is currently 3.12. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from OXFORD BIOMEDICA partners.

Analysis of OXFORD BIOMEDICA

Latest potential upside is at 5.94. As of the 17th of September 2020, OXFORD BIOMEDICA holds the Semi Deviation of 2.83, risk adjusted performance of 0.0758, and Mean Deviation of 2.41. Concerning fundamental indicators, the technical analysis model allows you to check practical technical drivers of OXFORD BIOMEDICA, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for OXFORD BIOMEDICA, which can be compared to its competitors. Please check OXFORD BIOMEDICA standard deviation, value at risk, kurtosis, as well as the relationship between the jensen alpha and semi variance to decide if OXFORD BIOMEDICA is priced more or less accurately, providing market reflects its current price of 11.0 per share. Given that OXFORD BIOMEDICA has jensen alpha of 0.1064, we recommend you to check out OXFORD BIOMEDICA's recent market performance to make sure the company can sustain itself at some point in the future.

Although other entities under the biotechnology industry are still a bit expensive, OXFORD BIOMEDICA may offer a potential longer-term growth to shareholders. To conclude, as of the 17th of September 2020, we see that OXFORD BIOMEDICA follows the market closely. The firm is overvalued with very small chance of distress within the next 24 months. Our primary 30 days 'Buy-Sell' recommendation on the firm is Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of OXFORD BIOMEDICA. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com